VISEN Pharmaceuticals (Stock Code: 02561) published its monthly return for the period ended 30 November 2025. The filing shows an authorized share capital of 500,000,000 ordinary shares at par value USD 0.0001 each, totaling USD 50,000. The total issued share count remains unchanged at 113,926,864, with no treasury shares.

There were no new share issuances, warrants, or convertibles during the month. Under the Post-IPO Share Award Scheme, conditionally adopted on 16 November 2022, no additional shares were issued in November 2025. The maximum number of shares that may be issued under the scheme remains 2,399,500, with 435,000 shares granted in June 2025.